Algeta ASA: The Board of Directors of Algeta ASA confirms that it is in receipt of a preliminary acquisition proposal from Bayer AG
-
In response to recent media commentary, the Board of Directors of Algeta ASA confirms that it is in receipt of a preliminary acquisition proposal from Bayer AG.
-
The commentary in the media refers to an acquisition proposal at a price of NOK 306 per Algeta share. This is incorrect. The preliminary acquisition proposal is NOK 336 per Algeta share.
-
There is no certainty that this preliminary acquisition proposal will lead to a transaction or as to the terms of any such transaction.
Oslo, Norway, 26 November, 2013 - The Board of Directors of Algeta ASA (OSE: ALGETA) today announced that it is in receipt of a preliminary acquisition proposal from Bayer AG which may or may not lead to a transaction. Discussions are at an early stage and further announcements may be made, as appropriate, in due course.
###
For further information, please contact:
| Oystein Soug | +47 90 65 65 25 |
| CFO | |
| Mike Booth | +1 646 410 1884 |
| Communications & Corporate Affairs | [email protected] |
About Algeta
Algeta is a company focused on developing, manufacturing and marketing novel targeted therapies for patients with cancer. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.